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Each manuscript received by JACC is sent out to two or more
reviewers and is also reviewed by the Editor (or Associate
Editor) to whom it is assigned. Each Tuesday morning at our
weekly Editors’ meetings, manuscripts are reviewed relative to
suitability for publication. We always have more manuscripts
with good reviews than we can publish. Such manuscripts are
prioritized, thus resulting in the rejection of some manuscripts
that are quite good. This is a painful process for the Editors,
but is required by the fixed limitation of publication pages,
which are contractually agreed upon by the ACC and Elsevier.
When the recommendation of two reviewers is to reject a
manuscript, and the Editor concurs, it is very straightforward
to reject that manuscript. On the other hand, if a manuscript
receives high marks from both reviewers, and the Editor
concurs, then this manuscript is considered eligible for publi-
cation if its priority ranking relative to other such manuscripts
is high enough. Most of the manuscripts, however, are in the
gray zone between these two extreme examples. One reviewer
may give it high marks, whereas the other one gives it low
marks. In this circumstance, the input of the assigned Editor
and possibly a third reviewer is critical, although the consensus
judgment of all the Editors plays a major role when the
manuscript is presented at the Tuesday meeting.
Implicit in the above ranking process is that a manuscript
will not be accepted if both referees recommend rejection.
However, on rare occasions such a manuscript ends up being
published. Such is the case for two manuscripts published in
this issue of JACC (1,2). These are two of a series of articles
published by this group on nitrate tolerance. The conclusion of
one manuscript (1) is that carvedilol essentially prevented
the development of nitrate tolerance in patients with chronic
heart failure. This provocative finding is thought to result
from the antioxidant properties of carvedilol. One of the key
assays in this interpretation is platelet cyclic guanosine-39,59-
monophosphate (GMP). Both referees who reviewed this
article indicated that they tried to reproduce this assay and
could not do so, thus leading to their recommendation for
rejection. A third referee, who reviewed all of the materials,
recommended publication. All three referees are experts in the
area of heart failure and nitrate tolerance. Because JACC has
no mechanism for independently verifying the accuracy of an
assay, we must make an independent decision based on our
review of the article itself, together with the referees’ com-
ments. We were somewhat reassured with this article by the
concordance of forearm blood flow measurements and the
platelet cyclic GMP measurements, but remained concerned
with the reviews of the two experts who apparently could not
reproduce the assay.
After consulting with editors of two other journals, and
discussing this situation in detail with the Associate Editors, I
elected to accept the articles, and accompany them with this
Editor’s Page. The data are potentially of great importance to
the management of heart failure and deserve to be published.
Furthermore, the data have considerable importance in the
area of angina and ischemic heart disease, where nitrates and
beta-adrenergic blocking agents are used together frequently.
By calling attention to concerns regarding the assay, however,
it is hoped that this issue can be resolved by other investigators
evaluating the reproducibility and utility of this assay. As
always, I welcome your comments on issues like this that relate
to our acceptance policies of the Journal and ways by which
they can be improved.
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